Online
AACE’s Advanced Diabetes Technology – Conversations and Collaborations is designed to equip endocrine care team members with evidence-based knowledge and increased competence about how to use diabetes technology and devices to guide and modify treatment approaches for persons with diabetes. Completion of this self-paced course is encouraged prior to attending a live session as it provides foundational information that will be built upon in the live program.
Starts 8/10/2022 | Expires 8/9/2023
Target Audience
This educational initiative is intended for all members of the endocrine care team.
Learning Objectives
Through this education, learners will improve their abilities to:
- Assess differences and best uses for continuous glucose monitors (CGMs), insulin pumps, and integrated devices.
- Discuss appropriate settings for CGMs, connected pens, insulin pumps, and integrated devices.
- Identify interventions which can add value to A1c interpretation and optimize “in-target” glucose values to improve patient adherence and reduce the occurrent of dysglycemia.
- Incorporate diabetes technologies that are effective in managing patients in special populations and individual needs.
- Navigate insurance challenges when implementing diabetes technologies.
Commercial Support
This activity is supported by independent educational grants from Abbott Diabetes Care, Dexcom, Lilly, Medtronic, and Novo Nordisk.
Faculty
 |
Matthew J. Levine, MD, FACE |
 |
Jeffrey R. Unger, MD FAAFP, FACE |
 |
Lucy H. Thornton, MSN, APRN, FNP-BC |
 |
Claire Ingram, PA-C |
Accreditation and Designation Statements
Accreditation and Designation
Physicians
The American College of Endocrinology designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses/Nurse Practitioners
This activity is approved for 1.0 contact hour(s) of continuing education (which includes 0 hour(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 22085650. This activity was planned in accordance with AANP Accreditation Standards and Policies.
Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC Medical Knowledge point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
Statement of Need
This initiative is designed to equip endocrine care team members with evidence-based knowledge and increased competence about how to use diabetes technology and devices to guide and modify treatment approaches for patients with diabetes.
Disclosures/Conflicts of Interest
Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, The American Association of Clinical Endocrinology (AACE)requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. AACE resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, AACE seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. AACE is committed to providing learners with high-quality CME.
Faculty
Matthew Levine, MD, FACE, Novo Nordisk, speakers' bureau on diabetes; Eli Lilly, speakers' bureau on diabetes; Mannkind, consultant
Jeff Unger, MD, FAAFP, FACE, Abott Diabetes, consultant and speakers' bureau; Dexcom, consultant
Claire Ingram, PA-C, no relationships to disclose
Lucy Thornton, MSN, APRN, FNP-BC, no relationships to disclose
All of the relevant financial relationships listed for these individuals have been mitigated.
Planners
Amy Ogunsunlade, no relationships to disclose
Diane Alberson, MEd, CAE, no relationships to disclose
Contributer/Reviewer
Carla Cox, PhD, RDN, FADCES, Certified Diabetes Care and Education Specialist (CDCES), Certified Insulin Pump and CGM Trainer Mountain Vista Medicine, South Jordan, UT American Diabetes Association, Arlington, VA
Carla Cox, PhD, RDN, FADCES has no relevant financial relationships to disclose.
Disclosure of Unlabeled Use
AACE requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. AACE does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
